4.5 Article

Lefty inhibits glioma growth by suppressing Nodal-activated Smad and ERK1/2 pathways

Journal

JOURNAL OF THE NEUROLOGICAL SCIENCES
Volume 347, Issue 1-2, Pages 137-142

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2014.09.034

Keywords

Lefty; Nodal; Glioma; Smad; ERK1/2; Tumor

Funding

  1. China Natural Science Foundation [81201976]
  2. Jiangsu Province's Natural Science Foundation [BK2012670]
  3. Jiangsu Province's Medical Science Program [z2013180]

Ask authors/readers for more resources

As a common malignant tumor, glioma has long been a refractory disease in the field of neurosurgery. Exploration of its etiology, pathogenesis, biological characteristics, and new treatment measures is a hot topic as well as a problem most difficult to solve in the neurosurgical division. In recent years, the role of Nodal and its feedback inhibitor Lefty in tumors has drawn more and more attention and may form a new target for cancer therapy. Western blot detection indicated that there was almost no expression of Lefty protein in glioma cells. Transfection of Lefty-overexpressing vector into GBM8401 and GBM glioma cells significantly decreased the expression of Nodal. Nodal can significantly increase the phosphorylation levels of Smad2 and Smad3 and activate the ERK1/2 pathway; meanwhile, Nodal promotes the proliferation and invasion of glioma cells and inhibits their apoptosis. However, when cells were co-transfected with both Lefty- and Nodal-overexpressing vectors, Lefty inhibited the above effects of Nodal in glioma cells, hence significantly reduced the levels of phosphorylated Smad2,Smad3, and ERK1/2, inhibited the proliferation and invasion of glioma cells, and increased their apoptosis. These results indicate that in glioma cells, Lefty inhibits Nodal-mediated activation of Smad and ERK1/2 signaling pathways, thereby suppressing the promoting effect of Nodal on tumor growth. (C) 2014 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available